ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
42 announcements
Q2FY27 consolidated revenue INR 2,735 Cr (+17.3%), PAT INR 317 Cr (+4.0%, 11.6% margin); H1 revenue INR 5,280 Cr (+17.4%). Net debt/EBITDA 0.87x. Expansion via Suguna acquisition and SLJ Delhi agreement.
Fortis Healthcare released a press release on Q2 FY27 results, with consolidated revenue of INR 2,735 Cr up 17.3%. It also disclosed the Suguna Hospital acquisition and a 400+ bed Delhi hospital services agreement.
Fortis Healthcare approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026 at its board meeting on November 5, 2026. The filing encloses the results and a limited review report with an emphasis on a SFIO fraud investigation.
Fortis Healthcare's Chief Growth & Innovation Officer, Dr. Ritu Garg, resigned effective close of business on October 31, 2026. The resignation is a senior management personnel change with no monetary impact stated.
Fortis Healthcare will hold a board meeting on 5 November 2026 to approve Q2 and half-year unaudited results and alter terms of ₹1,550 Crore listed NCDs. The filing is a prior intimation of the board meeting with agenda items only.
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
Fortis Healthcare's wholly-owned subsidiary IHL acquired Suguna Hospital's business and land in Bengaluru via slump sale. The cumulative consideration is approximately INR 277 Crore, consummated today.
Fortis Healthcare Ltd filed its quarterly shareholding pattern for the quarter ended 30th September 2026 as per SEBI regulatory requirements.
Fortis Hospotel will acquire 26% of Clean Max Sau Pvt Ltd for ₹1.85 Crore. The SPV develops a captive solar project in Haryana for energy cost optimization.
Subsidiary acquired 26% of an SPV for a captive solar project in Haryana. Investment of up to Rs. 1.85 Crore meets the company's green energy needs.
Fortis Healthcare files its half-yearly statement of listed debt securities as on September 30, 2026. Three NCD tranches maturing December 2029 remain outstanding with floating coupon rates.
Northern TK Venture Pte Ltd, Fortis Healthcare's promoter, has appealed a Tokyo District Court judgment to the Tokyo High Court. The litigation concerns losses related to delayed tender offer approvals.
Fortis Hospotel signed definitive agreements with SLJ Society to provide healthcare services at their 400+ bed hospital. Fortis will provide a ₹567 Crore loan.
Tokyo District Court dismissed all NTK claims against Daiichi Sankyo; NTK must bear litigation costs. NTK is reviewing the judgment and evaluating appeal options.
Management conference call discussing a Delhi High Court order regarding a forensic audit. Operating plans, including capex, bed expansion, and M&A, remain unaffected and fully funded by internal accruals.
The Delhi High Court has ordered a forensic audit concerning shareholding changes and control of Fortis Healthcare's erstwhile promoters. The company faces no liability or penalty.
Fortis Healthcare Limited received a voluntary ESG rating for FY 2025-26 from Crisil ESG Ratings & Analytics Ltd, with a rating category of 'Strong'.
Fortis Healthcare held its 30th Annual General Meeting on August 11, 2026. Shareholders considered resolutions for financial statement adoption, a Rs. 1 per share dividend, and director re-appointments.
Fortis Q1FY27 consolidated revenue grew 17.5% YoY to INR 2,545 Cr. Consolidated Operating EBITDA rose 15.8% to INR 568 Cr with a 22.3% margin.
Fortis Healthcare reported consolidated revenues of INR 2,545 Crore for Q1 FY27. The company's press release highlights operational performance across its hospital and diagnostics business segments.
Fortis Healthcare Ltd reported revenue from operations of ₹2,545 Cr (+17.5% YoY) and net profit of ₹272.8 Cr (+2.2% YoY) for Q1 FY27.
Fortis Healthcare's board approved the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, and appointed new tax auditors.
Fortis Healthcare Limited announced an intra-group merger involving its material subsidiary, Agilus Diagnostics Limited, and two of its wholly-owned subsidiaries.
Fortis Healthcare Limited announced a board meeting on August 06, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026.
Fortis Healthcare Ltd filed its quarterly shareholding pattern as of June 30, 2026. The report details holdings across promoter, institutional, and public categories.
Fortis Healthcare announced the appointment of Mr. Vijender Singh as MD and CEO of its subsidiary, Agilus Diagnostics, effective July 20, 2026.
Fortis Healthcare fixed July 24, 2026, as the record date for a ₹1 per share final dividend. Payment is subject to shareholder approval at the upcoming AGM.
Fortis Healthcare convened its 30th AGM for August 11, 2026. Key agendas include dividend declaration and re-appointment of Dr. Ashutosh Raghuvanshi as Managing Director.
Fortis Healthcare re‑appoints Dr. Ashutosh Raghuvanshi as CEO effective 19‑Mar‑2027 for a 24‑month term. The change was approved in the board meeting on 8‑Jul‑2026.
Fortis Healthcare's Board re‑appointed Dr. Ashutosh Raghuvanshi as Managing Director and CEO for two years from 19 Mar 2027. The decision was disclosed on 8 July 2026.